PT - JOURNAL ARTICLE ED - , TI - Once-daily triple therapy inhaler for COPD AID - 10.1136/dtb.2018.4.0611 DP - 2018 Apr 01 TA - Drug and Therapeutics Bulletin PG - 42--45 VI - 56 IP - 4 4099 - http://dtb.bmj.com/content/56/4/42.short 4100 - http://dtb.bmj.com/content/56/4/42.full SO - Drug Ther Bull2018 Apr 01; 56 AB - â–¼Trelegy Ellipta (GSK) is a dry powder inhaler containing fluticasone furoate (inhaled corticosteroid [ICS]), vilanterol trifenatate (long-acting beta2 agonist [LABA]) and umeclidinium bromide (long-acting muscarinic antagonist [LAMA]).1 It is licensed for once-daily use as maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. Here, we consider the evidence for this combination product and discuss how it fits with current management strategies.